Table:
text: Cancer immunotherapy
Types of monoclonal antibodies
Cancer immunotherapy:Monoclonal antibodies
Antibody Brand_name Approval_date Type_ Target Approved_treatments
Alemtuzumab Campath 2001 humanized CD52 Chronic lymphocytic leukemia
Bevacizumab Avastin 2004 humanized vascular endothelial growth factor colorectal cancer
Brentuximab vedotin Adcetris 2011 chimeric CD30 Hodgkin lymphoma , Anaplastic large-cell lymphoma
Cetuximab Erbitux 2004 chimeric epidermal growth factor receptor colorectal cancer
Gemtuzumab ozogamicin Mylotarg 2000 humanized CD33 acute myelogenous leukemia (with calicheamicin )
Panitumumab Vectibix 2006 human epidermal growth factor receptor colorectal cancer
Rituximab Rituxan, Mabthera 1997 chimeric CD20 non-Hodgkin lymphoma

Question: What are all approved treatments for targeting CD30 in cancer immunotherapy?

Question: What is the brand name of the antibody brentuximab vedotin under cancer immunotherapy?

Question: How many targets are there in cancer immunotherapy with an approval date of 1997?

Question: What are the approved treatments when the antibody is bevacizumab for cancer immunotherapy?

Question: What is the goal of cancer immunotherapy approved in 2006?